http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Rishi Agarwal,Kimberly Koenig,Eric Rohren,Vivek Subbiah 한국유방암학회 2014 Journal of breast cancer Vol.17 No.3
Metaplastic breast cancer (MpBC) is an extremely rare breastcancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, noveltargeted therapies should be explored. Herein, we report theclinical course of a 59-year-old African American woman withMpBC with a PIK3CA mutation in codon 545, exon 10 (GAG toAAG; p.Glu545Lys) and a TP53 mutation in codon 286, exon 8(GAA to AAA; p.Glu286Lys). The same mutations were observedin the primary and secondary sites. The patient wastreated with a molecularly matched therapy using a combinedantiangiogenic and mammalian target of rapamycin kinase inhibitorstrategy that included liposomal doxorubicin, bevacizumab,and temsirolimus. Partial remission was achieved. Inthis report, the scientific rationale underlying the activity of thiscombination was explored. In conclusion, patients may benefitfrom being offered molecular profiling early during the course ofthe disease to receive a therapy guided accordingly.